Aarti Drugs Share Price | Aarti Drugs Stock Screener
AARTIDRUGS
Pharmaceuticals
Share Price NSE
₹410.00
▼
-2.00 (-0.49%)
Share Price BSE
₹408.90
▼
-3.65 (-0.88%)
As of July 23, 2026, the Aarti Drugs share price (NSE: AARTIDRUGS) is ₹410.00 on NSE and ₹408.90 on BSE, down 0.49% from the previous close, with shares trading between ₹406.55 and ₹414.85, and a 52-week range of ₹319.75–₹539.05.
Analyse AARTIDRUGS share price history and track historical price performance.
Use the Aarti Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Aarti Drugs Market Cap
₹3,821.93 Cr.
AARTIDRUGS P/E Ratio (TTM)
19.80
Aarti Drugs P/B Ratio
2.49
EPS (TTM)
₹21.36
Dividend Yield
0.47%
Debt to Equity
0.44
AARTIDRUGS 52 Week High
₹539.05
Aarti Drugs 52 Week Low
₹319.75
Operating Margin
13.00%
Profit Margin
7.63%
AARTIDRUGS Revenue (TTM)
₹721.00
EBITDA
₹97.00
Net Income
₹55.00
Total Assets
₹2,815.00
Total Equity
₹1,549.00
Aarti Drugs Share Price Chart
Screen Aarti Drugs share price with an interactive chart. Analyse AARTIDRUGS price trends and volatility across different timeframes.
Aarti Drugs Company Profile - Fundamental Screener
Screen Aarti Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AARTIDRUGS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE767A01016
Aarti Drugs Balance Sheet Screener
Screen AARTIDRUGS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,815 | 2,575 | 2,432 | 2,421 | 2,208 | 1,766 | 1,577 | 1,456 | 1,389 | 1,191 |
| Current Assets | 1,468 | 1,338 | 1,321 | 1,492 | 1,393 | 1,057 | 900 | 784 | 737 | 571 |
| Fixed Assets | 1,300 | 866 | 811 | 676 | 690 | 665 | 644 | 625 | 602 | 581 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 344 | 368 | 355 | 296 | 232 | 257 | 301 | 321 | 312 | 297 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,549 | 1,369 | 1,282 | 1,193 | 1,036 | 913 | 653 | 543 | 455 | 400 |
| Share Capital | 91 | 91 | 92 | 93 | 93 | 93 | 23 | 24 | 24 | 24 |
| Reserves & Surplus | 1,458 | 1,278 | 1,190 | 1,100 | 944 | 820 | 629 | 520 | 432 | 376 |
Aarti Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Aarti Drugs income statement and profit fundamentals.
Analyze AARTIDRUGS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aarti Drugs share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 721 | 603 | 653 | 591 | 679 | 569 | 600 | 557 | 621 | 608 | 642 | 662 | 743 | 665 | 688 |
| Expenses | 625 | 547 | 569 | 516 | 583 | 495 | 531 | 490 | 534 | 536 | 565 | 577 | 649 | 593 | 614 |
| EBITDA | 97 | 56 | 84 | 74 | 95 | 74 | 69 | 66 | 87 | 72 | 77 | 85 | 94 | 72 | 74 |
| Operating Profit % | 13.00% | 9.00% | 13.00% | 13.00% | 14.00% | 11.00% | 11.00% | 12.00% | 14.00% | 12.00% | 12.00% | 13.00% | 13.00% | 11.00% | 11.00% |
| Depreciation | 18 | 18 | 16 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 13 | 13 | 13 | 13 | 13 |
| Interest | 8 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 9 | 9 | 9 |
| Profit Before Tax | 70 | 29 | 60 | 51 | 71 | 51 | 46 | 44 | 64 | 52 | 56 | 64 | 73 | 50 | 53 |
| Tax | 15 | -12 | 15 | -3 | 8 | 14 | 11 | 11 | 17 | 15 | 17 | 16 | 17 | 13 | 14 |
| Net Profit | 55 | 41 | 45 | 54 | 63 | 37 | 35 | 33 | 47 | 37 | 40 | 48 | 56 | 37 | 39 |
| EPS | 6.05 | 4.44 | 4.95 | 5.91 | 6.88 | 4.06 | 3.83 | 3.62 | 5.15 | 3.99 | 4.29 | 5.18 | 6.07 | 3.96 | 4.18 |
Aarti Drugs Cash Flow Screener - Liquidity Fundamentals
Screen AARTIDRUGS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 245 | 359 | 133 | 70 | 155 | 251 | 143 | 70 | 175 | 133 |
| Investing Activities | -165 | -224 | -164 | -150 | -72 | -33 | -62 | -74 | -107 | -99 |
| Financing Activities | -82 | -136 | 17 | 92 | -81 | -215 | -80 | 4 | -68 | -33 |
| Net Cash Flow | -2 | -1 | -14 | 13 | 2 | 2 | 1 | 0 | 0 | 1 |
Aarti Drugs Shareholding Pattern Screener
See Aarti Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Aarti Drugs promoter holding and ownership changes for AARTIDRUGS on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 55.03% | 55.03% | 54.72% | 55.22% | 55.48% | 55.38% | 55.64% | 55.67% |
| FII Holding | 1.58% | 2.15% | 2.69% | 2.26% | 2.25% | 2.28% | 2.50% | 2.96% |
| DII Holding | 10.22% | 10.12% | 9.90% | 9.94% | 9.70% | 8.77% | 7.84% | 7.35% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.72% | 23.43% | 23.58% | 23.69% | 23.51% | 24.32% | 24.80% | 24.75% |
| Other Holding | 9.46% | 9.27% | 9.11% | 8.89% | 9.06% | 9.24% | 9.21% | 9.27% |
| Shareholder Count | 144,946 | 148,363 | 152,252 | 160,260 | 169,761 | 176,006 | 190,281 | 150,218 |
Aarti Drugs Share Dividend Screener - Share Yield Analysis
Check Aarti Drugs dividend history with payout and yield data.
View Aarti Drugs dividend details including ex-dates and amounts for AARTIDRUGS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.31% |
| 2024-March | ₹1.00 | 0.29% |
| 2023-March | ₹1.00 | 0.23% |
| 2022-March | ₹1.00 | 0.30% |
| 2021-March | ₹2.50 | 0.58% |
| 2020-March | ₹2.00 | 0.29% |
| 2019-March | ₹1.00 | 0.80% |
| 2018-March | ₹1.00 | 0.63% |
| 2017-March | ₹1.00 | 0.79% |
Aarti Drugs Stock Index Membership
See which indices include Aarti Drugs stock.
Check AARTIDRUGS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Aarti Drugs Market Events Screener - Corporate Actions
Get Aarti Drugs corporate actions including splits, bonuses, and buybacks.
Check Aarti Drugs stock events that may affect AARTIDRUGS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | -8.73% |
| 2026-02-09 | 2026-02-09 | Dividend | ₹ 2.00 /share | -2.32% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 3.65% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -2.61% |
| 2025-09-24 | 2025-09-24 | Annual General Meeting | NA | 9.35% |
| 2025-07-18 | 2025-07-18 | Quarterly Result Announcement | NA | 7.28% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-04 | 2025-02-04 | Dividend | ₹ 1.00 /share | 8.52% |
| 2025-01-29 | 2025-01-29 | Quarterly Result Announcement | NA | -8.06% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -3.19% |
| 2024-09-20 | 2024-09-20 | Annual General Meeting | NA | -11.02% |
| 2024-09-05 | 2024-09-11 | Buyback | 900 | 2.86% |
| 2024-02-06 | 2024-02-06 | Dividend | ₹ 1.00 /share | -2.89% |
| 2023-08-04 | 2023-08-09 | Buyback | 900 | 2.45% |
| 2023-02-08 | 2023-02-08 | Dividend | ₹ 1.00 /share | -3.11% |
Aarti Drugs Competitors Screener - Peer Comparison
Screen AARTIDRUGS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 468,950 | 40.30 | 61,674 | 12.69% | 11,565 | 62.67 |
| Divis Laboratories | 194,204 | 75.03 | 10,560 | 8.73% | 2,520 | 69.61 |
| Torrent Pharmaceuticals | 189,423 | 75.44 | 13,886 | 20.34% | 2,138 | 53.08 |
| Cipla | 116,726 | 29.67 | 29,045 | 2.24% | 3,870 | 48.42 |
| Zydus Life Science | 115,918 | 22.25 | 27,658 | 17.64% | 5,026 | 59.19 |
| Lupin | 113,266 | 20.85 | 29,039 | 26.75% | 5,356 | 54.70 |
| Mankind Pharma | 105,743 | 53.09 | 14,636 | 14.85% | 1,938 | 50.34 |
| Dr Reddys Laboratories | 102,314 | 24.31 | 35,059 | 3.90% | 4,158 | 31.90 |
| Aurobindo Pharma | 90,104 | 25.44 | 33,385 | 3.21% | 3,376 | 50.49 |
| Laurus Labs | 84,196 | 92.82 | 6,868 | 22.01% | 890 | 59.60 |
Aarti Drugs Company Announcements - News Screener
Screen AARTIDRUGS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-23 | Closure Directions By GPCB | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-27 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-16 | Transfer Of Equity Shares Of The Company To IEPF | - |
| 2026-06-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-26 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-16 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-15 | Re-Appointment Of Cost Auditor And Internal Auditor | - |
| 2026-05-15 | Board Meeting Outcome for Outcome Of The Board Meeting Dated May 15 2026 | - |
| 2026-05-15 | Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-08 | Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-04-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |